Stay updated with breaking news from Graphite Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Gene therapy clinical trial pipeline constitutes 250+ key companies continuously working towards developing 300+ gene therapies, analyzes DelveInsight LAS VEGAS, Nov. 2, 2022 /PRNewswire/
/PRNewswire/ -- DelveInsight's 'Gene Therapy Competitive Landscape – 2022' report provides comprehensive global coverage of available, marketed, and pipeline...
While worthy advances have recently been made in sickle cell disease, companies such as Graphite Bio, bluebird bio, Vertex Pharmaceuticals and Editas Medicine have loftier ambitions.
Graphite Bio, Inc. (NASDAQ:GRPH) is a clinical-stage gene editing company based in San Francisco, California. It develops therapies for life-threatening diseases in the United States.
/PRNewswire/ -- The overall Fabry disease market is likely to surge owing to the increasing prevalence of the disease along with the promising emerging...